EK
Eliyahu Sharon Kalif
EVP, Chief Financial Officer

Eliyahu Sharon Kalif insider trades: Teva Pharmaceutical Industries (TEVA) stock sales

EVP, Chief Financial Officer, Teva Pharmaceutical Industries Last trade Jun 11, 2026 29 Form 4 filings
$15.3M
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2022
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Eliyahu reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 11, 2026TEVA↓ Sell$3.6M
Feb 26, 2026TEVA↓ Sell$11.6M
Jun 12, 2025TEVA↓ Sell$952K
Feb 28, 2025TEVA↓ Sell$903K
Mar 6, 2024TEVA↓ Sell$1.0M
Aug 7, 2023TEVA↓ Sell$342K
Aug 22, 2022TEVA↓ Sell$559K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other TEVA insiders

Open-market trades in the last 12 months

About Eliyahu Sharon Kalif's insider trades

Eliyahu Sharon Kalif is EVP, Chief Financial Officer at Teva Pharmaceutical Industries (TEVA). Since Aug 22, 2022, Eliyahu has reported no open-market purchases and 7 sales worth $19.1M on SEC Form 4. In the last 12 months: 2 sales ($15.3M).

Their filings also include option exercises (17 filings), grants and awards (12 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TEVA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.